Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

Massimo Gentile*, Tait D. Shanafelt, Francesca Romana Mauro, Gianluigi Reda, Davide Rossi, Luca Laurenti, Maria Ilaria Del Principe, Giovanna Cutrona, Ilaria Angeletti, Marta Coscia, Yair Herishanu, Annalisa Chiarenza, Stefano Molica, Stefania Ciolli, Neta Goldschmidt, Francesco Angrilli, Annamaria Giordano, Angela Rago, Osnat Bairey, Giovanni TripepiKari G. Chaffee, Parikh A. Sameer, Ernesto Vigna, Katja Zirlik, Lev Shvidel, Idanna Innocenti, Anna Grazia Recchia, Francesco Di Raimondo, Giovanni Del Poeta, Agostino Cortelezzi, Antonino Neri, Manlio Ferrarini, Gianluca Gaidano, Neil E. Kay, Aaron Polliack, Robin Foà, Fortunato Morabito

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)703-706
Number of pages4
JournalEuropean Journal of Haematology
Volume101
Issue number5
DOIs
StatePublished - Nov 2018

Keywords

  • CLL-IPI
  • PFS
  • chemo-immunotherapy
  • chronic lymphocytic leukemia
  • prognosis
  • progression-free survival

Cite this